Neograft was founded to translate promising research in tissue engineering and regenerative medicine into real and useful solutions. Our first product, Angioshield, addresses inherent limits associated with using veins for coronary bypass surgery. The underlying science, discovered at the University of Pittsburgh, provides a foundation for many other new products.¹
CABG remains the best alternative for most patients with diffuse coronary vascular disease. Still, outcomes are compromised by the mechanical and biological limitations of veins typically used to create the bypass grafts.
Veins normally contain blood flowing back to the heart at low pressures. When used as arterial bypass grafts, veins are exposed to much higher pressures, causing a sequence of responses that commonly lead to occlusion of the vessel. Using current methods, 25% of these grafts fail within 12–18 months.² Within 5 years, the failure rate can be more than 40%.³
Our Angioshield technology creates a support layer around the vein using a novel process called electrospinning. The process is performed during surgery using a proprietary polymer that improves both the strength and geometric uniformity of the vein graft. The scaffold is highly conformal, supporting the vein without deforming its natural shape; its high porosity allows nutrients and new cells to migrate into and through the support layer.
Over time, new, stronger tissue develops around and within the scaffold. In parallel, the polymer weakens to allow the new tissue to be exposed to its normal environment — favoring development of stronger, more functional tissues.⁴
¹ Biomaterials 2008;29:3213-20 ² Circulation 2014;130:1445-51. ³ Ann Cardiothorac Surg 2013;2(4):427-30. ⁴ Data on file. Manuscript in press.
“Angioshield™ is a new paradigm for treatment of coronary artery disease and promises to improve vein performance and longevity in coronary artery bypass grafts.”